Elsevier

The Lancet Neurology

Volume 16, Issue 7, July 2017, Pages 490-491
The Lancet Neurology

Comment
Edaravone: a new treatment for ALS on the horizon?

https://doi.org/10.1016/S1474-4422(17)30163-1Get rights and content

References (7)

There are more references available in the full text version of this article.

Cited by (61)

  • Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases

    2021, Neuroscience and Biobehavioral Reviews
    Citation Excerpt :

    The variability in terms used by patients to describe their discomfort highlights the complexity of pain in ALS and suggests the need for careful questioning on the part of providers when investigating symptoms in these patients. FDA-approved treatments for ALS include riluzole, dextromethorphan/quinidine, and recently edaravone (Hardiman and van den Berg, 2017; Writing and Edaravone, 2017), which have been shown to improve survival (Miller et al., 2012), provide relief from pseudobulbar symptoms (Brooks et al., 2004), and improve functioning (Hardiman and van den Berg, 2017; Writing and Edaravone, 2017). To date, there are no RCTs of pain management in ALS (Brettschneider et al., 2013).

  • Progress in progestin-based therapies for neurological disorders

    2021, Neuroscience and Biobehavioral Reviews
View all citing articles on Scopus
View full text